Kite Pharma licenses technology for development of off-the-shelf allogeneic T-cell therapy
Kite Pharma announced it has entered into an exclusive, worldwide license agreement with The Regents of the University of California, on behalf of the UCLA, for technology to advance development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells. July 25, 2016